Skip to main content

The Multiple Faces of Glucagon-Like Peptide-1—Obesity, Appetite, and Stress: What Is Next? A Review

Digestive Diseases and Sciences volume 52, pages 643–649 (2007)Cite this article

Abstract

By itself, glucagon-like peptide-1(GLP-1) appears to be an excellent drug for appetite control and the treatment of obesity. Unfortunately, few enzymes, such as IV dipeptidyl peptidase and renal excretin, degrade and render GLP-1 inactive within minutes. A receptor agonist, exendin-4, with a longer biological half-life than GLP-1, has been tried. Subcutaneous injection of exendin-4 or continuous IV injection of GLP-1 warrants further research and investigation.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3

References

  1. Perry T, Lahiri DK, Chen D, et al. (2002) A novel neurotrophic property of glucagon-like peptide-1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 300:958–966

    PubMed  Article  CAS  Google Scholar 

  2. Fehmann HC, Göke R, Göke B (1995) Cell and molecular biology of the incretin hormones glucagon-like peptide 1 and glucose-dependent insulin releasing polypeptide. Endocr Rev 16:390–410

    PubMed  Article  CAS  Google Scholar 

  3. Naslund E, Hellstrom PM (1998). Glucagon-like peptide-1 in the pathogenesis of obesity. Drug News Perspect 11:92–97

    PubMed  Article  CAS  Google Scholar 

  4. Gutzwiller JP, Tschopp S, Bock A, et al. (2004) Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrin Metab 89:3055–3061

    Article  CAS  Google Scholar 

  5. Eissele R, Goke R, Willemer S, et al. (1992) Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 22:283–291

    PubMed  CAS  Article  Google Scholar 

  6. Jin SL, Han VK, Simmons JG, et al. (1988) Distribution of glucagon-like peptide-1 (GLP-1), glucagon, and glicentin in the rat brain: an immunocytochemical study. J Comp Neurol 271:519–532

    PubMed  Article  CAS  Google Scholar 

  7. Merchenthaler I, Lane M, Shughrue P (1999) Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 403:261–280

    PubMed  Article  CAS  Google Scholar 

  8. Rouille Y, Martin S, Steiner DF (1995) Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide. J Biol Chem 270:26488–26496

    PubMed  Article  CAS  Google Scholar 

  9. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF (1992) Insulinotropic action of glucagon-like peptide-1-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 15:270–276

    PubMed  CAS  Google Scholar 

  10. Holst JJ (1997) Enteroglucagon. Annu Rev Physiol 59:257–271

    PubMed  Article  CAS  Google Scholar 

  11. Kreymann B, Williams G, Ghatei MA, et al. (1987) Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2:1300–1304

    PubMed  Article  CAS  Google Scholar 

  12. Yoshimoto S, Hirota M, Ohboshi C, et al. (1989) Identification of glucagon-like peptide-1 (7-36) amide in rat brain. Ann Clin Biochem 26:169–171

    PubMed  CAS  Google Scholar 

  13. Ørskov C, Rabenhøj L, Wettergren A, et al. (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43:535–539

    PubMed  Google Scholar 

  14. Mojsov S, Kopczynski MG, Habener JF (1990) Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas. J Biol Chem 265:8001–8008

    PubMed  CAS  Google Scholar 

  15. Kreymann B, Ghatei MA, Burnet P, et al. (1989) Characterization of glucagon-like peptide 1-(7-36)amide in the hypothalamus. Brain Res 502:325–331

    PubMed  Article  CAS  Google Scholar 

  16. Ritzel R, Ørskov C, Holst JJ, et al. (1995) Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose–response-relationships. Diabetologia 38:720–725

    PubMed  CAS  Google Scholar 

  17. Creutzfeldt WO, Kleine N, Willms B, et al. (1996) Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I [7-36 amide] in type I diabetic patients. Diabetes Care 19:580–586

    PubMed  CAS  Google Scholar 

  18. Näslund E, Bogefors J, Skogar S, et al. (1999) GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 277:R910–916

    PubMed  Google Scholar 

  19. Flint A, Raben A, Ersboll AK, et al. (2001) The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 25:781–792

    PubMed  Article  CAS  Google Scholar 

  20. Meier S, Hucking K, Titzel R, et al. (2003) Absence of a memory effect for the insulinotropic action of glucagon-like peptide-1 (GLP-1) in healthy volunteers. Horm Met Res 35:551–556

    Article  CAS  Google Scholar 

  21. Silvestre RA, Rodriguez-Gallardo J, Egido EM, et al. (2003) Interrelationship among insulin, glucagon and somatostatin secretory responses to exendin-4 in the perfused rat pancreas. Eur J Pharmacol 469:195–200

    PubMed  Article  CAS  Google Scholar 

  22. Ling Z, Wu D, Zambre Y, et al. (2001) Glucagon-like peptide-1 receptor signalling influences topography of islet cells in mice. Virchows Archiv 438:382–387

    PubMed  Article  CAS  Google Scholar 

  23. Nagai K, Tsuchiya K, Ezaki T, et al. (2004) Effect of GLP-1 (glucagon-like peptide-1:7-36 amide) on porcine pancreatic endocrine cell proliferation and insulin secretion. Pancreas 28:138–145

    PubMed  Article  CAS  Google Scholar 

  24. Meier JJ, Gallwitz B, Schmidt WE, Nauck MA (2002) Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. Eur J Pharmacol 440:269–279

    PubMed  Article  CAS  Google Scholar 

  25. Kieffer TJ, McIntosh CH, Pederson RA (1995) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585–3596

    PubMed  Article  CAS  Google Scholar 

  26. Gutzwiller JP, Goke B, Drewe J, et al. (1999) Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 44:81–86

    PubMed  CAS  Article  Google Scholar 

  27. Gutzwiller JP, Drewe J, Goke B, et al. (1999) Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 276:R1541–1544

    PubMed  CAS  Google Scholar 

  28. Toft-Nielsen MB, Madsbad S, Holst JJ (1999) Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22:1137–1143

    PubMed  CAS  Google Scholar 

  29. Verdich C, Toubro S, Buemann B, et al. (2001) The role of postprandial releases of insulin and incretin hormones in meal-induced satiety—effect of obesity and weight reduction. Int J Obes Relat Metab Disord 25:1206–1214

    PubMed  Article  CAS  Google Scholar 

  30. Flint A, Raben A, Ersboll AK, Holst JJ, Astrup A (2001) The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 25:781–792

    PubMed  Article  CAS  Google Scholar 

  31. Kalra SP, Dube MG, Pu MG, et al. (1999) Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocrine Rev 20:68–100

    Article  CAS  Google Scholar 

  32. Schwartz MW, Baskin DG, Kaiyala KJ, et al. (1999) Model for the regulation of energy balance and adiposity by the central nervous system. Am J Clin Nutr 69:584–596

    PubMed  CAS  Google Scholar 

  33. Meeran K, O’Shea D, Edwards CM, et al. (1999) Repeated intracerebroventricular administration of glucagon-like peptide-1-(7–36) amide or exendin-(9–39) alters body weight in the rat. Endocrinology 140:244–250

    PubMed  Article  CAS  Google Scholar 

  34. Larsen PJ, Tang-Christensen M, Jessop DS (1997) Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 138:4445–4455

    PubMed  Article  CAS  Google Scholar 

  35. Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M, et al. (2004) Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145:2687–2695

    PubMed  Article  CAS  Google Scholar 

  36. Shughrue PJ, Lane MV, Merchenthaler I (1996) Glucagon-like peptide-1 receptor (GLP-1-R) mRNA in the rat hypothalamus. Endocrinology 137:5159–5162

    PubMed  Article  CAS  Google Scholar 

  37. Dakin CL, Small CJ, Park AJ, et al. (2002) Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. Am J Physiol 283:E1173–1177

    CAS  Google Scholar 

  38. Dakin CL, Gunn I, Small CJ, et al. (2001) Oxyntomodulin inhibits food intake in the rat. Endocrinology 142:4244–4250

    PubMed  Article  CAS  Google Scholar 

  39. Dakin CL, Small CJ, Park AJ, et al. (2002) Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. Am J Physiol 283:E1173–1177

    CAS  Google Scholar 

  40. Tang-Christensen M, Vrang N, Larsen PJ (2001) Glucagon-like peptide containing pathways in the regulation of feeding behaviour. Int J Obes Relat Metab Disord 25[Suppl 5]:S42–47

    PubMed  CAS  Article  Google Scholar 

  41. Fehmann HC, Jiang J, Schweinfurth J, et al. (1994) Stable expression of the rat GLP-I receptor in CHO cells: activation and binding characteristics utilizing GLP-I (7–36) -amide, oxyntomodulin, exendin-4, and exendin (9–39). Peptides 15:453–456

    PubMed  Article  CAS  Google Scholar 

  42. Dakin CL, Small CJ, Batterham RL, et al. (2004) Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145:2687–2695

    PubMed  Article  CAS  Google Scholar 

  43. Yamamoto H, Kishi T, Lee CE, et al. (2003) Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci 23:2939–2946

    PubMed  CAS  Google Scholar 

  44. Cohen MA, Ellis SM, Le Roux CW, et al. (2003) Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 88:4696–701

    PubMed  Article  CAS  Google Scholar 

  45. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR (1985) Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89:1070–1077

    PubMed  CAS  Google Scholar 

  46. Sarkar S, Fekete C, Legradi G, et al. (2003) Glucagon-like peptide-1 (7-36) amide (GLP-1) nerve terminals densely innervate corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Brain Res 985:163–168

    PubMed  Article  CAS  Google Scholar 

  47. Alvarez E, Roncero I, Chowen JA, et al. (1996) Expression of the glucagon-like peptide-1 receptor gene in rat brain. J Neurochem 66:920–997

    PubMed  CAS  Article  Google Scholar 

  48. Møller C, Sommer W, Thorsell A, et al. (2002) Anxiogenic-like action of centrally administered glucagon-like peptide-1 in a punished drinking test. Prog Neuropsychopharmacol Biol Psychiatry 26:119–122

    PubMed  Article  Google Scholar 

  49. Kinzig KP, D’Alessio DA, Herman JP, et al. (2003) CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors. J Neurosci 23:6163–6170

    PubMed  CAS  Google Scholar 

  50. Malendowicz LK, Nussdorfer GG, Nowak KW, et al. (2003) Exendin-4, a GLP-1 receptor agonist, stimulates pituitary-adrenocortical axis in the rat: investigations into the mechanism(s) underlying Ex4 effect. Int J Mol Med 12:237–241

    PubMed  CAS  Google Scholar 

  51. Rinaman L (1999) Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus. Am J Physiol 277:R582–590

    PubMed  CAS  Google Scholar 

  52. MacLusky NJ, Cook S, Scrocchi L, et al. (2000) Neuroendocrine function and response to stress in mice with complete disruption of glucagon-like peptide-1 receptor signaling. Endocrinology 141:752–762

    PubMed  Article  CAS  Google Scholar 

  53. Andreis PG, Malendowicz LK, Neri G, et al. (1999) Effects of glucagon and glucagon-like peptide-1 on glucocorticoid secretion of dispersed rat adrenocortical cells. Life Sci 64:2187–2197

    PubMed  Article  CAS  Google Scholar 

  54. Peters CT, Choi YH, Brubaker PL, et al. (2001) A glucagon-like peptide-1 receptor agonist and an antagonist modify macronutient selection by rats. J Nutr 131:2164–2170

    PubMed  CAS  Google Scholar 

  55. Iritani N, Sugimoto T, Fukuda H, Komiya M, Ikeda H (1999) Oral triacylglycerols regulate plasma glucagon-like peptide-1(7-36) and insulin levels in normal and especially in obese rats. J Nutrition 129:46–50

    CAS  Google Scholar 

  56. Vilsboll T, Krarup T, Sonne J, et al. (2003) Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 88:2706–2713

    PubMed  Article  CAS  Google Scholar 

  57. Vilsboll T, Agerso H, Krarup T, et al. (2003) Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88:220–224

    PubMed  Article  CAS  Google Scholar 

  58. Velasquez-Mieyer PA, Cowan PA, Umpierrez GE, et al. (2003) Racial differences in glucagon-like peptide-1 (GLP-1) concentrations and insulin dynamics during oral glucose tolerance test in obese subjects. Int J Obes Relat Metab Disord 27:1359–1364

    PubMed  Article  CAS  Google Scholar 

  59. Feinle C, Chapman IM, Wishart J, et al. (2002) Plasma glucagon-like peptide-1 (GLP-1) responses to duodenal fat and glucose infusions in lean and obese men. Peptides 23:1491–1495

    PubMed  Article  CAS  Google Scholar 

  60. Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V (1996) Attenuated GLP-1 secretion in obesity: cause or consequence? Gut 38:916

    PubMed  CAS  Google Scholar 

  61. Tomasik PJ, Sztefko K, Malek A (2002) GLP-1 as a satiety factor in children with eating disorders. Horm Metab Res 34:77–80

    PubMed  CAS  Google Scholar 

  62. Lugari R, Dei Cas A, Ugolotti D, et al. (2004) Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion. Horm Metab Res 36:111–115

    PubMed  Article  CAS  Google Scholar 

  63. Fukase N, Igarashi M, Takahashi H, et al. (1993) Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients. Diabet Med 10:44–49

    PubMed  CAS  Google Scholar 

  64. Feinle C, Chapman IM, Wishart J, et al. (2002) Plasma glucagon-like peptide-1 (GLP-1) responses to duodenal fat and glucose infusions in lean and obese men. Peptides 23:1491–1495

    PubMed  Article  CAS  Google Scholar 

  65. Velasquez-Mieyer PA, Cowan PA, Umpierrez GE, et al. (2003) Racial differences in glucagon-like peptide-1 (GLP-1) concentrations and insulin dynamics during oral glucose tolerance test in obese subjects. Int J Obes Relat Metab Disord 27:1359–1364

    PubMed  Article  CAS  Google Scholar 

  66. Lugari R, Dei Cas A, Ugolotti D, et al. (2004) Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion. Horm Metab Res 36:111–115

    PubMed  Article  CAS  Google Scholar 

  67. Navarro M, Rodriguez de Fonseca F, Alvarez E, et al. (1996) Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transported GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J Neurochem 67:1982–1991

    PubMed  CAS  Article  Google Scholar 

  68. Meier JJ, Gallwitz B, Schmidt WE, et al. (2002) Glucagon-like peptide-1 as a regulator of food intake and body weight: therapeutic perspectives. Eur J Pharmacol 440:269–279

    PubMed  Article  CAS  Google Scholar 

  69. Larsen PJ, Vrang N, Tang-Christensen M (2003) Central pre-proglucagon derived peptides: opportunities for treatment obesity. Curr Pharm Des 9:1373–1382.

    PubMed  Article  CAS  Google Scholar 

  70. Young AA, Gedulin BR, Bhavsar S, et al. (1999) Glucose-lowering and insulin-sensitizing actions of Exendin-4: Studies in obese diabetic (ob(ob, db(db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48:1026–1034

    PubMed  CAS  Google Scholar 

  71. Szayna M, Doyle ME, Betkey JA, et al. (2000) Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141:1936–1941

    PubMed  Article  CAS  Google Scholar 

  72. Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M (2001) Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 50:2530–2539

    PubMed  CAS  Google Scholar 

  73. Naslund E (2004) Prandial subcutaneous injections of GLP-1 cause weight loss in obese human subjects. Br J Nutr 91:439–446

    PubMed  Article  CAS  Google Scholar 

  74. Grandt D, Schimiczek M, Beglinger C, Layer P, Goebell H, Eysselein VE, et al. (1994) Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. Regul Pept 51:151–159

    PubMed  Article  CAS  Google Scholar 

  75. Batterham RL, Cowley MA, Small CJ, et al. (2002) Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418:650–654

    PubMed  Article  CAS  Google Scholar 

  76. Halatchev IG, Ellacott KL, Fan W, et al. (2004) Peptide YY3-36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism. Endocrinology 145:2585–2590

    PubMed  Article  CAS  Google Scholar 

  77. Kojima M, Hosoda H, Date Y, et al. (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656–660

    PubMed  Article  CAS  Google Scholar 

  78. Guan XM, Yu H, Palyha OC, McKee KK, Feighner SD, Sirinathsinghji DJ, et al. (1997) Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Brain Res Mol Brain Res 48:23–29

    PubMed  Article  CAS  Google Scholar 

  79. Katayama M, Nogami H, Nishiyama J, Kawase T, Kawamura K (2000) Developmentally and regionally regulated expression of growth hormone secretagogue receptor mRNA in rat brain and pituitary gland. Neuroendocrinology 72:333–340

    PubMed  Article  CAS  Google Scholar 

  80. Shintani M, Ogawa Y, Ebihara K, et al. (2001) Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y(Y1 receptor pathway. 50:227–232

  81. Clark JT, Kalra PS, Kalra SP (1985) Neuropeptide Y stimulates feeding but inhibits sexual behavior in rats. Endocrinology 117:2435–2442

    PubMed  CAS  Article  Google Scholar 

  82. Cummings DE, Purnell JQ, Frayo RS, et al. (2001) A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50:1714–1719

    PubMed  CAS  Google Scholar 

  83. Wren AM, Seal LJ, Cohen MA, et al. (2001) Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86:5992

    PubMed  Article  CAS  Google Scholar 

  84. Nakazato M, Murakami N, Date Y, et al. (2001) A role for ghrelin in the central regulation of feeding. Nature 409:194–198

    PubMed  Article  CAS  Google Scholar 

  85. Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, Taheri S, et al. (2000) The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 141:4325–4328

    PubMed  Article  CAS  Google Scholar 

  86. Wren AM, Small CJ, Abbott CR, Dhillo WS, Seal LJ, Cohen MA, et al. (2001) Ghrelin causes hyperphagia and obesity in rats. Diabetes 50:2540–2547

    PubMed  CAS  Google Scholar 

  87. Laferrere B, Abraham C, Russell CD, et al. (2005) Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab 90:611–614

    PubMed  Article  CAS  Google Scholar 

  88. Frezza EE (2004) Are we closer in finding the treatment for type ii diabetes mellitus in morbid obesity—are the incretins the key to success? Obesity Surgery 14:999–1005

    PubMed  Article  Google Scholar 

  89. Cummings DE, Shannon MH (2003) Ghrelin and gastric bypass: is there a hormonal contribution to surgical weight loss? J Clin Endocrinol Metab 88:2999–3002

    PubMed  Article  CAS  Google Scholar 

  90. Rubino F, Gagner M, Gentileschi P, Kini S, Fukuyama S, Feng J, et al. (2004) The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 240:236–242

    PubMed  Article  Google Scholar 

  91. Naslund E, Gryback P, Hellstrom PM, Jacobsson H, Holst JJ, Theodorsson E, et al. (1997) Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. Int J Obes Relat Metab Disord 21:387–392

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Division of General Surgery, Department of Surgery, Texas Tech University Health Sciences Center, MOP Building, Suite 380, 3502 9th Street, Lubbock, TX, 79145, U.S.A.

    Eldo E. Frezza MD, MBA, FACS

  2. Department of Pathology, Texas Tech University, Health Sciences Center, San Antonio, U.S.A.

    Mitchell S. Wachtel MD

  3. Department of Microbiology and Immunology, Texas Tech University, Health Sciences Center, San Antonio, U.S.A.

    Maurizio Chiriva-Internati Phd

Authors
  1. Eldo E. Frezza MD, MBA, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mitchell S. Wachtel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maurizio Chiriva-Internati Phd
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eldo E. Frezza MD, MBA, FACS.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Frezza, E.E., Wachtel, M.S. & Chiriva-Internati, M. The Multiple Faces of Glucagon-Like Peptide-1—Obesity, Appetite, and Stress: What Is Next? A Review. Dig Dis Sci 52, 643–649 (2007). https://doi.org/10.1007/s10620-006-9096-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-006-9096-2

Keywords

  • GLP-1
  • Ghrelin
  • Type 2 diabetes
  • Obesity
  • Bariatric surgery
  • Incretins
  • Satiety
  • Appetite
  • Stress
  • Oxyntomodulin